Related references
Note: Only part of the references are listed.COVID-19 in Immunocompromised Hosts: What We Know So Far
Monica Fung et al.
CLINICAL INFECTIOUS DISEASES (2021)
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines
Christopher Pleyer et al.
BLOOD (2021)
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
Laurence Chu et al.
VACCINE (2021)
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2021)
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
Evangelos Terpos et al.
BLOOD (2021)
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
Fulvia Pimpinelli et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Leticia Monin et al.
LANCET ONCOLOGY (2021)
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
Lindsey E. Roeker et al.
LEUKEMIA (2021)
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies
Paola Ghione et al.
BLOOD (2021)
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
Lee M. Greenberger et al.
CANCER CELL (2021)
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer
Sidse Ehmsen et al.
CANCER CELL (2021)
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
Deborah Steensels et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
Erin M. Bange et al.
NATURE MEDICINE (2021)
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
H. Parry et al.
BLOOD CANCER JOURNAL (2021)
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
Kazimieras Maneikis et al.
LANCET HAEMATOLOGY (2021)
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
Sean H. Lim et al.
LANCET HAEMATOLOGY (2021)
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
Mounzer E. Agha et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine
Nathan E. Richards et al.
JAMA NETWORK OPEN (2021)
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study
Ron Ram et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy
Astha Thakkar et al.
NATURE CANCER (2021)
Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma
Clive S. Zent et al.
LEUKEMIA (2021)
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti et al.
LANCET HAEMATOLOGY (2020)
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
Carolyn Rydyznski Moderbacher et al.
CELL (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma
Hajime Yasuda et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Abi Vijenthira et al.
BLOOD (2020)
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
Alemnew F. Dagnew et al.
LANCET INFECTIOUS DISEASES (2019)
Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies
Janie Parrino et al.
VACCINE (2017)
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
Hugues de Lavallade et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)